Post-sepsis state induces tumor-associated macrophage accumulation through CXCR4/CXCL12 and favors tumor progression in mice

Cancer Immunology Research

Volumn 4, Issue 4, 2016, Pages 312-322

  Mota, José M ^a   Leite, Caio A ^a   Souza, Lucas E ^a   Melo, Paulo H ^a   Nascimento, Daniele C ^a   De Deus Wagatsuma, Virginia M ^a   Temporal, Jessica ^a   Figueiredo, Florêncio ^b   Noushmehr, Houtan ^a   Alves Filho, José C ^a   Cunha, Fernando Q ^a   Rego, Eduardo M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF BRASILIA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCYTE CHEMOTACTIC PROTEIN 1; STROMAL CELL DERIVED FACTOR 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; IN VIVO STUDY; MALE; MELANOMA B16; MOUSE; NEOPLASM; NONHUMAN; PROTEIN BLOOD LEVEL; SEPSIS; SURVIVAL TIME; TUMOR ASSOCIATED LEUKOCYTE; ANIMAL; COMPLICATION; DISEASE COURSE; DISEASE MODEL; EXPERIMENTAL MELANOMA; IMMUNOLOGY; MACROPHAGE; METABOLISM; METASTASIS; PATHOLOGY;

ANIMALS; CHEMOKINE CXCL12; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION; MACROPHAGES; MALE; MELANOMA, EXPERIMENTAL; MICE; NEOPLASM METASTASIS; NEOPLASMS; RECEPTORS, CXCR4; SEPSIS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84964330598     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0170     Document Type: Article

References (52)

1. Beale R, Reinhart K, Brunkhorst FM, Dobb G, Levy M, Martin G, et al. Promoting Global Research Excellence in Severe Sepsis (PROGRESS): lessons from an international sepsis registry. Infection 2009;37:222-32.
2. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41:580-637.
3. Weycker D, Akhras KS, Edelsberg J, Angus DC, Oster G. Long-term mortality andmedical care charges in patients with severe sepsis. Crit Care Med 2003;31:2316-23.
4. Quartin AA, Schein RM, Kett DH, Peduzzi PN. Magnitude and duration of the effect of sepsis on survival. Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group. JAMA 1997;277:1058-63.
5. Otto GP, Sossdorf M, Claus RA, Rödel J, Menge K, Reinhart K, et al. The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit Care. 2011;15:R183.
6. Nascimento DC, Alves-Filho JC, Sônego F, Fukada SY, Pereira MS, Benjamim C, et al. Role of regulatory T cells in long-term immune dysfunction associated with severe sepsis. Crit Care Med 2010;38:1718-25.
7. Munoz C, Carlet J, Fitting C, Misset B, Blériot JP, Cavaillon JM. Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest 1991;88:1747-54.
8. Carson WF, Cavassani KA, Dou Y, Kunkel SL. Epigenetic regulation of immune cell functions during post-septic immunosuppression. Epigenetics 2011;6:273-83.
9. Döcke WD, Höflich C, Davis KA, Röttgers K, Meisel C, Kiefer P, et al. Monitoring temporary immunodepression by flow cytometric measurement of monocytic HLA-DR expression: a multicenter standardized study. Clin Chem 2005;51:2341-7.
10. Takahashi H, Tsuda Y, Takeuchi D, Kobayashi M, Herndon DN, Suzuki F. Influence of systemic inflammatory response syndrome on host resistance against bacterial infections. Crit Care Med 2004;32:1879-85.
11. Dahlke E, Murray CA, Kitchen J, Chan A-W. Systematic review of melanoma incidence and prognosis in solid organ transplant recipients. Transplant Res 2014;3:10.
12. Cavassani KA, Carson WF, Moreira AP, Wen H, Schaller MA, Ishii M, et al. The post sepsis-induced expansion and enhanced function of regulatory T cells create an environment to potentiate tumor growth. Blood 2010;115:4403-11.
13. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat Rev Immunol 2013;13:862-74.
14. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
15. Cavallo F, De Giovanni C, Nanni P, Forni G Lollini P-L. 2011: the Immune Hallmarks of Cancer. Cancer Immunol Immunother 2011;60:319-26.
16. Coussens LM, Werb Z. Inflammation and cancer. Nature 2010;420:860-7.
17. Biswas SK, Allavena P, Mantovani A. Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin Immunopathol 2013;35:585-600.
18. Zhang Q, Liu L, Gong C, Shi H, Zeng Y, Wang X, et al. Prognostic significance of tumor-associated macrophages in solid tumor: a metaanalysis of the literature. PLoS One 2012;7:e50946.
19. Cortez-Retamozo V, Etzrodt M, Newton A, Rauch PJ, Chudnovskiy A, Berger C, et al. Origins of tumor-associated macrophages and neutrophils. Proc Natl Acad Sci 2012;109:2491-6.
20. Tymoszuk P, Evens H, Marzola V, Wachowicz K, Wasmer M-H, Datta S, et al. In situ proliferation contributes to accumulation of tumor-associated macrophages in spontaneous mammary tumors. Eur J Immunol 2014;44:2247-62.
21. Schioppa T, Uranchimeg B, Saccani A, Biswas SK, Doni A, Rapisarda A, et al. Regulation of the chemokine receptor CXCR4 by hypoxia. J Exp Med 2003;198:1391-402.
22. Knowles H, Harris AL. Macrophages and the hypoxic tumour microenvironment. Front Biosci 2007;12:4298-314.
23. Hubbard WJ, Choudhry M, Schwacha MG, Kerby JD, Rue LW, Bland KI, et al. Cecal Ligation and Puncture. Shock 2005;24:52-7.
24. Jacob D, Davis J, Fang B. Xenograftic tumor models in mice for cancer research, a technical review. Gene Ther Mol Biol 2004;8:213-9.
25. Ketcham A, Kinsey D, Wexler H, Mantel N. The development of spontaneous metastases after the removal of a "primary" tumor. II. Standardization protocol of 5 animal tumors. Cancer 1961;14:875-82.
26. Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015;1-13.
27. Solinas G, Germano G, Mantovani A, Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 2009;86:1065-73.
28. Loberg RD, Ying C, Craig M, Yan L, Snyder LA, Pienta KJ. CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia 2007;9:556-62.
29. Qian B, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011;475:222-5.
30. Cho HJ, Jung JI, Lim DY, Kwon GT, Her S, Park JH, et al. Bone marrowderived, alternatively activated macrophages enhance solid tumor growth and lung metastasis of mammary carcinoma cells in a Balb/C mouse orthotopic model. Breast Cancer Res 2012;14:R81.
31. Bimal S, Sinha S, Singh SK, Narayan S, Kumar V, VermaN, et al. Leishmania donovani: CD2 biased immune response skews the SAGmediated therapy for a predominant Th1 response in experimental infection. Exp Parasitol 2012;131:274-82.
32. Oh J, Riek AE, Weng S, Petty M, Kim D, Colonna M, et al. Endoplasmic reticulum stress controls M2 macrophage differentiation and foam cell formation. J Biol Chem 2012;287:11629-41.
33. Cho SG, AttayaM, Monaco JJ. New class II-like genes in the murine MHC. Nature 1991;353:573-6.
34. Qu C, Brinck-Jensen NS, Zang M, Chen K. Monocyte-derived dendritic cells: Targets as potent antigen-presenting cells for the design of vaccines against infectious diseases. Int J Infect Dis [Internet] 2014;19:1-5.
35. Leng L, Metz CN, Fang Y, Xu J, Donnelly S, Baugh J, et al. MIF signal transduction initiated by binding to CD74. J Exp Med 2003;197:1467-76.
36. Widera G, Flavell RA. The nucleotide sequence of the murine I-E beta b immune response gene: evidence for gene conversion events in class II genes of the major histocompatibility complex. EMBO J 1984;3:1221-5.
37. Cavnar MJ, Zeng S, Kim TS, Sorenson EC, Ocuin LM, Balachandran VP, et al. KIT oncogene inhibition drives intratumoral macrophageM2polarization. J Exp Med 2013;210:2873-86.
38. Tchernychev B, Furie B, Furie BC. Peritoneal macrophages express both P-selectin and PSGL-1. J Cell Biol 2003;163:1145-55.
39. Lacaze P, Raza S, Sing G, Page D, Forster T, Storm P, et al. Combined genome-wide expression profiling and targeted RNA interference in primary mouse macrophages reveals perturbation of transcriptional networks associated with interferon signalling. BMC Genomics 2009;10:372.
40. Tomioka H, Tatano Y, Maw WW, Sano C, Kanehiro Y, Shimizu T. Characteristics of suppressor macrophages induced by mycobacterial and protozoal infections in relation to alternatively activatedM2 macrophages. Clin Dev Immunol 2012;2012:635451.
41. Karlsson L, Peterson PA. The alpha chain gene of H-2O has an unexpected location in the major histocompatibility complex. J Exp Med 1992;176:477-83.
42. Han X, Wilbanks GD, Devaja O, Ruperelia V, Raju KS. IL-2 enhances standard IFNgamma/LPS activation of macrophage cytotoxicity to human ovarian carcinoma in vitro: a potential for adoptive cellular immunotherapy. Gynecol Oncol 1999;75:198-210.
43. Sica A, Mantovani A. Macrophage plasticity and polarization: In vivo veritas. J Clin Invest 2012;122:787-95.
44. Lu XJ, Chen J, Yu CH, Shi YH, He YQ, Zhang RC, et al. LECT2 protects mice against bacterial sepsis by activatingmacrophages via the CD209a receptor. J Exp Med 2013;210:5-13.
45. Mauer J, Chaurasia B, Goldau J, Vogt MC, Ruud J, Nguyen KD, et al. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nat Immunol 2014;15:423-30.
46. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002;23:549-55.
47. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep 2014;6:13.
48. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Front Biosci 2008;13:453-61.
49. Bierie B, Moses HL. Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev 2010;21:49-59.
50. Wang J, Guan E, Roderiquez G, Calvert V, Alvarez R, Norcross M. Role of tyrosine phosphorylation in ligand-independent sequestration of CXCR4 in human primary monocytes-macrophages. J Biol Chem 2001;276:49236-43.
51. Beider K, Bitner H, Leiba M, Gutwein O, Koren-Michowitz M, Ostrovsky O, et al. Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype. Oncotarget 2014;5:11283-96.
52. Zhou J, Ding T, Pan W, Zhu L-Y, Li L, Zheng L. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer 2009;125:1640-8.